drugset / Trial / NCT00021736

Phase II/III Study of Anti-VEGF in Neovascular AMD

NCT00021736

Phase 2/3 Completed 540 enrolled Eyetech Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD

Timeline

Start
2001-07
Primary completion
Completion
2002-07

Drugs

EvaluationDrugModalityDoseRoute
Subject pegaptanib sodium Aptamer Intravitreal